Cystoscopy without the aid of urinary markers is the most cost-effective strategy for detecting recurrence of non-invasive bladder cancer, according to researchers. In a study that examined five ...
Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
A simple urine test can more than halve the number of cystoscopies necessary to follow up high-risk bladder cancer patients, new research has found. Cystoscopies involve inserting a flexible probe ...
A new urine test could spare bladder cancer survivors from a painful follow-up procedure needed to ensure their cancer hasn't come back, researchers report. People who've gotten surgery for high-risk ...
In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate ...
Bladder cancer affects more than 86,000 people in the United States each year, according to the American Cancer Society, with the majority being over age 55. And while the disease can often be ...
A urine test was shown to decrease the need for invasive cystoscopies in patients with non-muscle-invasive bladder cancer. A urine-based test may decrease the number of invasive cystoscopies in ...
New urine test can improve accuracy for early detection of bladder cancer in patients with hematuria
A streamlined urine DNA test more accurately detects primary bladder cancer, reducing the need for more invasive cystoscopy, reports The Journal of Molecular Diagnostics Lead investigator Sungwhan An, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results